Coherus Biosciences | CHRS - Nettoeinkommen





Nettoeinkommen Veränderung Datum
AbbVie USD 695M 1.12B 2026-03
Acadia Pharmaceuticals USD 3.64M 269.93M 2026-03
Akebia Therapeutics USD -12.24M 12.78M 2025-12
ALKERMES USD -66.48M 115.82M 2026-03
Alnylam Pharmaceuticals USD 205.99M 19.57M 2026-03
Amarin USD -1.22M 6.51M 2025-12
Amgen USD 1.82B 486M 2026-03
Baxter International USD -15M 1.11B 2026-03
Biogen USD 319.5M 368.4M 2026-03
BioMarin Pharmaceutical USD 105.53M 152.1M 2026-03
Bristol-Myers Squibb USD 2.68B 1.59B 2026-03
Coherus Biosciences USD -37.64M 2.11M 2025-12
Eli Lilly USD 7.4B 760M 2026-03
Fujifilm JPY 84.24B 11.58B 2026-03
Gilead Sciences USD 2.02B 162M 2026-03
Ironwood Pharmaceuticals USD 3.19M 457K 2024-12
Merck USD -4.24B 7.2B 2026-03
Myriad Genetics USD -7.9M 19.5M 2025-12
Pacira USD 2.92M 1.28M 2026-03
Perrigo USD -398.6M 1.02B 2026-03
Pfizer USD 2.69B 4.34B 2026-03
PTC Therapeutics USD -2.81M 132.16M 2026-03
Regeneron Pharmaceuticals USD 727.2M 117.4M 2026-03
Sarepta Therapeutics USD 330.96M 743.18M 2026-03
Teva Pharmaceutical Industries USD 369M 111M 2026-03
Vertex Pharmaceuticals USD 1.03B 159.7M 2026-03
Xencor USD -128.92M 122.26M 2026-03
Zoetis USD 601M 2M 2026-03